Ariad Pharmaceuticals Inc fka ARIA

[biotech_researcher]

We are in the top four of ASH:

Lordy, this should move the stock...

This year, there was no new data or ideas expounded in the sessions I chose, they were basically a run through of the old data with a couple of slides at the end listing a few compounds that are in development. The pipeline in for hematologic malignancies is gradually gaining more attention from Pharma, which is great news, although they are probably a lot less crowded than the main solid tumours.
The Leukemia press briefing was informative and a number of abstracts were selected for discussion. All of the presenters did an excellent job of summarising their data, which is embargoed until after the Plenary or Oral sessions on Sunday and Monday.
The leukemia highlights comprised:

Dr Fielding: imatinib in Ph+ pediatric ALL

Dr Rosti: nilotinib in Ph+ early phase adult CML

Dr Cortes: ponatinib in advanced phase CML


Anna Jankowska and Prof Maciejewski: TET2 mutations in myeloid malignancies

I will write more about the data after the embargoes have been lifted.

http://pharmastrategyblog.com/2010/12/highlights-of-ash2010-day-1.html/?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+PharmaStrategyBlog+%28Pharma+Strategy+Blog%29